Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Phase Ia/Ib study of BI 765883 in metastatic pancreatic ductal adenocarcinoma
jRCT2031240308Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Modality
- Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of BI 765883 in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Dose-limiting toxicities (DLTs) during the MTD evaluation period. Started Oct 2024; status: active, not recruiting.
02
Drugs
BI 765883
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031240308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240308.